Loading…
Passage Bio, Inc. is projected to rise to $4.71 by 2027, a +5% move from its current price of $4.49. PASG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.32 | $4.49 | $4.67 | +0.05% |
| Aug 6 | $4.26 | $4.49 | $4.74 | +0.10% |
| Aug 7 | $4.21 | $4.50 | $4.80 | +0.15% |
| Aug 8 | $4.17 | $4.50 | $4.85 | +0.19% |
| Aug 9 | $4.13 | $4.50 | $4.90 | +0.24% |
| Aug 10 | $4.10 | $4.50 | $4.94 | +0.29% |
| Aug 11 | $4.07 | $4.51 | $4.98 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.07 | $4.51 | $4.98 | +0.34% |
| Week 2 | $3.92 | $4.52 | $5.21 | +0.68% |
| Week 3 | $3.81 | $4.54 | $5.40 | +1.02% |
| Week 4 | $3.72 | $4.55 | $5.57 | +1.37% |
| Week 5 | $3.65 | $4.57 | $5.72 | +1.71% |
| Week 6 | $3.58 | $4.58 | $5.86 | +2.06% |
| Week 7 | $3.52 | $4.60 | $6.00 | +2.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Passage Bio, Inc. is a healthcare company focused on genetic medicines. It develops gene therapies for central nervous system diseases, including PBFT02, a functional GRN and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
The company also develops PBML04 for metachromatic leukodystrophy and PBAL05 for the treatment of amyotrophic lateral sclerosis, with other programs for Huntington’s disease. Passage Bio was incorporated in 2017 and is based in Philadelphia, Pennsylvania. It has strategic research collaborations and development/clinical supply agreements with institutions such as the Trustees of the University of Pennsylvania’s Gene Therapy Program and Catalent Maryland, Inc.
This is a healthcare company focused on core CNS genetic medicines programs and collaborations within the biotech space, operating from its Philadelphia base since 2017. It emphasizes pursuing multiple gene-therapy programs across several neurodegenerative conditions.
Passage Bio, Inc. (PASG) is a healthcare stock currently priced at $4.62 per share with a market cap of $14.84M and a market rank of 4791. The stock sits in the lower end of the market-cap spectrum among listed equities, reflecting its relatively small capitalization.
The price outlook in the provided forecast shows a path from a 2026 average of $4.62 up to a 2050 average of $24.25, with several years labeled bullish and others neutral. Notable mid- to long-term milestones include a 2028 average of $5.86, 2029 average of $8.00, and a steep rise to 2040 average of $12.93 and 2050 average of $24.25, with a max forecast reaching $54.83 by 2050.
The forecast also presents year-by-year min/max values and corresponding sentiment, indicating a generally upward trajectory after 2027 and a broad upside potential over the long term, albeit with variability in earlier years. These figures are estimates and not guarantees of future performance.
A major floor 29.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 36.3% above — a clean break opens room to run.
A major ceiling 164.8% above — clearing it would confirm fresh momentum.
Key PASG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PASG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.53 | Sell | $4.56 | Sell |
| MA 10 | $4.71 | Sell | $4.64 | Sell |
| MA 20 | $4.72 | Sell | $4.76 | Sell |
| MA 50 | $5.14 | Sell | $5.20 | Sell |
| MA 100 | $6.09 | Sell | $6.07 | Sell |
| MA 200 | $8.01 | Sell | $7.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.30 | Neutral |
| Stoch RSI (14) | 1.86 | Buy |
| CCI (20) | -100.00 | Sell |
| Williams %R (14) | -94.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -8.96 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 6.00 | Buy |
| TRIX (15) | -0.43 | Sell |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 24.15 | Buy |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 4.40 | Buy |
| ADX (14) | 12.88 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is mixed, with a neutral sentiment overall. The RSI14 is 40, suggesting modest momentum. The 50-day simple moving average is $5.21 and the 200-day simple moving average is $8.10, indicating the price currently sits below longer-term averages.
Support is noted at $4.33 and a resistance level at $6.12. The 30-day price range runs from $3.46 to $6.16, outlining a narrow window in which the stock has traded recently. Investors should monitor how the price interacts with the $4.33 support and $6.12 resistance as volatility remains a factor given the stock’s profile.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.08 | $4.49 | $6.13 | 0% | Neutral | |
| $3.62 | $4.71 | $6.55 | +5% | Neutral | |
| $4.13 | $5.60 | $8.18 | +25% | Bullish | |
| $5.37 | $7.52 | $11.42 | +68% | Bullish | |
| $4.95 | $7.15 | $11.21 | +59% | Bullish | |
| $4.55 | $6.77 | $10.91 | +51% | Bullish | |
| $4.86 | $7.41 | $12.24 | +65% | Bullish | |
| $4.52 | $7.08 | $11.95 | +58% | Bullish | |
| $5.48 | $8.78 | $15.12 | +95% | Bullish | |
| $6.48 | $10.63 | $18.66 | +137% | Bullish | |
| $6.82 | $12.45 | $23.61 | +177% | Bullish | |
| $10.78 | $23.91 | $50.64 | +432% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.08 | $4.49 | $5.77 | +0.00% |
| September 2026 | $4.07 | $4.87 | $6.03 | +8.52% |
| October 2026 | $3.89 | $4.69 | $5.89 | -3.69% |
| November 2026 | $3.84 | $4.68 | $5.94 | -0.31% |
| December 2026 | $3.90 | $4.78 | $6.13 | +2.08% |
Click any year to see its month-by-month PASG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PASG to range from $4.08 to $6.13 through 2026. The $4.49 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PASG price prediction for 2027 points to an average of $4.71 (low $3.62, high $6.55) — a potential gain of +5% on today's $4.49. A consolidation phase looks the most probable path here.
In 2028, PASG is projected to trade between $4.13 and $8.18, averaging $5.60 — a potential gain of +25% from today's $4.49. That is up +19% on the projected 2027 average. Momentum favours further upside here.
Passage Bio, Inc.'s 2029 outlook centres on $7.52, within a $5.37 to $11.42 range. That is up +34% on the projected 2028 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PASG could reach as high as $11.21, with a base case around $7.15 and support toward $4.95 — roughly +59% from $4.49. Momentum favours further upside here.
Expect PASG to range from $4.55 to $10.91 through 2031. The $6.77 average target implies a +51% move from current prices. That is -5% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The PASG price prediction for 2032 points to an average of $7.41 (low $4.86, high $12.24) — a potential gain of +65% on today's $4.49. Momentum favours further upside here.
In 2033, PASG is projected to trade between $4.52 and $11.95, averaging $7.08 — a potential gain of +58% from today's $4.49. That is -5% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Passage Bio, Inc.'s 2034 outlook centres on $8.78, within a $5.48 to $15.12 range. That is up +24% on the projected 2033 average. That marks a +95% change versus current levels. Momentum favours further upside here.
By 2035, PASG could reach as high as $18.66, with a base case around $10.63 and support toward $6.48 — roughly +137% from $4.49. Buyers look set to stay in control over this stretch.
Expect PASG to range from $6.82 to $23.61 through 2040. The $12.45 average target implies a +177% move from current prices. That is up +17% on the projected 2035 average. Momentum favours further upside here.
The PASG price prediction for 2050 points to an average of $23.91 (low $10.78, high $50.64) — a potential gain of +432% on today's $4.49. Buyers look set to stay in control over this stretch.
Investing $1,000 in PASG today (≈ 222.717149 PASG) could be worth
$5,324.14
+$4,324.14 (+432%) by 2050 · US Dollar
Based on the average projected PASG price of $23.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PASGwould be worth at today's price.
$1,000 invested in PASG on Jul 31, 2025 (≈ 155.763238 PASG) would be worth
$699.38
-$300.62 (-30.1%) today · 0.70× · US Dollar
Based on a PASG entry price of $6.42 vs. today's $4.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.94 | $908.91 | -9.1% |
| 1 month ago | $4.58 | $980.35 | -2.0% |
| 3 months ago | $4.97 | $903.42 | -9.7% |
| 6 months ago | $12.07 | $372 | -62.8% |
| 1 year ago | $6.42 | $699.38 | -30.1% |
| All time (5.0y) ago | $252.8 | $17.76 | -98.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PASG forecast.
Our base-case forecast reaches $9.00 around 2035.
Implied market cap at $9.00: $28.92M
The multi-year forecast shows a bullish tilt from 2028 onward, with the average price rising to $5.86 in 2028, $8.00 in 2029, and $7.37 in 2030, before continuing to climb to $12.93 by 2040 and $24.25 by 2050. The corresponding ROI figures rise from 0 in 2026 to 59.6 in 2030, 179.9 by 2040, and 424.9 by 2050, reflecting a strong longer-term upside potential despite near-term fluctuations. The maximum forecasted price reaches $54.83 by 2050, with interim highs such as $20.57 in 2035 and $25.95 in 2040, illustrating meaningful upside under the scenario.
These are projections and not guarantees; the trajectory depends on numerous factors, including market conditions and company developments. The pattern indicates notable upside in the long run, balanced by periods of volatility and mixed signals in the near term.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $7.37, with a range of $4.90 to $12.01 and a ROI of 59.6; sentiment BULLISH.
The forecast shows bullish sentiment in many later years, with an average price rising to $24.25 by 2050 and a ROI of 424.9; however, 2026 is neutral with ROI 0, indicating mixed risk in the near term.
Yes. The forecast includes highs such as $20.57 in 2035 and reaches as high as $54.83 by 2050, with the 2050 average at $24.25 and a ROI of 424.9.
The current price is $4.62 and the market cap is $14.84M.
The 30-day range is $3.46 to $6.16.
Passage Bio, Inc. Community Discussion
0Share your Passage Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.